Safety, immunogenicity and infectivity of new live attenuated influenza vaccines

Expert Review of Vaccines

Volumn 14, Issue 10, 2015, Pages 1313-1329

  Isakova Sivak, Irina ^a   Rudenko, Larisa ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

immunogenicity; licensure criteria; live attenuated influenza vaccine; pandemic influenza; safety; seasonal influenza; vaccine virus shedding

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; CELL CULTURE; DEVELOPING COUNTRY; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); LICENSING; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; BLOOD; CELLULAR IMMUNITY; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; PANDEMICS; VACCINATION; VIROLOGY;

ANTIBODIES, VIRAL; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINATION; VACCINES, ATTENUATED;

EID: 84941804153     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1075883     Document Type: Review

References (118)

1. Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Imm 2015; 386: 151-180
2. Bardiya N, Bae JH. Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol 2005; 67 (3): 299-305
3. Traynor K. First recombinant flu vaccine approved. Am J Health Syst Pharm 2013; 70 (5): 382
4. Hayden FG, Howard WA, Palkonyay L, Kieny MP. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 2009; 27 (31): 4079-89
5. Jin H, Subbarao K. Live Attenuated Influenza Vaccine. In: Oldstone MBA, Compans RW.,. editors. Influenza Pathogenesis and Control. Volume 2 Springer International Publishing, Switzerland; 2015. p. 181-204
6. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod. Russia. J Infect Dis 1993; 168 (4): 881-7
7. Rudenko L, Slepushkin A, Monto A, et al. International Congress Series. Comparative studies of the efficacy of live attenuated and inactivated vaccines in children in Novgorod. Options for the control of influenza II. Excerpta Medica, Amsterdam; 1993. p. 85-90
8. Slepushkin A, Obrosova-Serova N, Burtseva E, et al. International Congress Series. Results of several controlled trials of live cold-adapted influenza A(H3N2) and influenza B vaccines for children in Moscow, 1987-1990. Options for the control of influenza II. Excerpta Medica, Amsterdam; 1993. p. 79-83
9. Smorodintseff AA, Tushinsky MD, Drobyshevskaya AI, et al. Investigation on volunteers infected with the influenza virus. Am J Med Sci 1937; 194 (2): 159-70
10. Aleksandrova GA, Klimov A. [Live Attenuated Influenza Vaccine]. "Nauka", Saint Petersburg 1994;151
11. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog Med Virol 1987; 34: 70-88
12. Alexandrova G. Basic trends in vaccination of children against influenza by use of live vaccine. Proc. Symposium on Live Influenza Vaccine, Yugoslav. Acad Sci Art 1971; 121-30
13. Alexandrova GI, Smorodintsev AA. Obtaining of an additionally attenuated vaccinating cryophilic influenza strain. Rev Roum Inframicrobiol 1965; 2: 179-89
14. Aleksandrova GI, Mikutskaia BA, Sirotenko EA, et al. [Results in the study of a special live influenza vaccine variant for the immunization of preschool and young school-age children]. Vestn Akad Med Nauk SSSR 1968; 23 (9): 41-5
15. Aleksandrova GI. [Use of the genetic recombination method for obtaining vaccinal strains of the influenza virus]. Vopr Virusol 1977; 4: 387-95
16. Kendal AP. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur J Epidemiol 1997; 13 (5): 591-609
17. Rudenko L, Alexandrova G. Current strategies for the prevention of influenza by the Russian cold-adapted live influenza vaccine among different populations. Int Congr Ser 2001; 1219: 945-50
18. Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999; 9 (4): 237-44
19. Garmashova LM, Polezhaev FI, Aleksandrova GI. [Cold-adapted strain of A/Leningrad/134/47/57 (H2N2)-a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants]. Vopr Virusol 1984; 29 (1): 28-31
20. Alexandrova GI, Polezhaev FI, Budilovsky GN, et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun 1984; 44 (3): 734-9
21. Grigoreva EP, Desheva Iu A, Donina SA, et al. [The comparative characteristics of the safety, immunogenic activity and prophylactic potency of the adult and children types of live influenza vaccine in schoolchildren aged 7-14 years]. Vopr Virusol 2002; 47 (4): 24-7
22. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19 (2-3): 308-18
23. Rudenko LG, Lonskaya NI, Klimov AI, et al. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 1996; 74 (1): 77-84
24. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature 1967; 213 (5076): 612-14
25. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011; 5 (2): 67-75
26. Beyer WE, Palache AM, De Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002; 20 (9-10): 1340-53
27. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204 (6): 845-53
28. Anonymous. Development of a clinical trial plan for pandemic influenza vaccines. Department of health and human services. National institute of allergy and infection diseases. September 22-23, 2003, Bethesda, Maryland. meeting summary. Available from: www.niaid.nih.gov/about/organization/dmid/Documents/pansummary.pdf
29. WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness 2014. Available from: http://who.int/influenza/vaccines/virus/201402h5h7h9h10vaccinevirusupdate.pdf?ua=1
30. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58 (4): 195-207
31. Chirkova TV, Naykhin AN, Petukhova GD, et al. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol 2011; 18 (10): 1710-18
32. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80 (23): 11756-66
33. WHO. Global pandemic influenza action plan to increase vaccine supply. Geneva, Belgium. WHO/IVB/06.13. WHO/ODS/EPR/GIP/2006.1. Available from: http://whqlibdoc.who.int/hq/2006/WHO-IVB-06.13-eng.pdf
34. Friede M, Palkonyay L, Alfonso C, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011; 29 (Suppl 1): A2-7
35. WHO. WHO global influenza preparedness plan. WHO/CDS/CSR/GIP/2005. 5. Available from: www.who.int/csr/resources/publications/influenza/en/WHOCDSCSRGIP20055.pdf
36. Coelingh KL, Luke CJ, Jin H, Talaat KR. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev Vaccines 2014; 13 (7): 855-71
37. Rudenko L, Isakova-Sivak I. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines 2015; 14 (3): 395-412
38. Rudenko L, Desheva J, Korovkin S, et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respir Viruses 2008; 2 (6): 203-9
39. Rudenko L, Kiseleva I, Stukova M, et al. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: Results from a placebo-controlled, randomized double-blind phase I study. Vaccine 2014; 9 (2): e87962
40. Rudenko L, Kiseleva I, Naykhin AN, et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: Results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One 2014; 9 (2): e87962
41. Isakova-Sivak I, Stukova M, Erofeeva M, et al. H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Hum Vaccin Immunother 2015; 11 (4): 970-82
42. Karron RA, Callahan K, Luke C, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009; 199 (5): 711-16
43. Talaat KR, Karron RA, Luke CJ, et al. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011; 29 (17): 3144-8
44. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27 (36): 4953-60
45. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 2009; 27 (28): 3744-53
46. Babu TM, Levine M, Fitzgerald T, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 2014; 32 (50): 6798-804
47. Talaat KR, Karron RA, Liang PH, et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013; 7 (1): 66-73
48. Wareing MD, Watson JM, Brooks MJ, Tannock GA. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol 2001; 65 (1): 171-7
49. Luke CJ, Subbarao K. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines 2014; 13 (7): 873-83
50. Girard MP, Katz JM, Pervikov Y, et al. Report of the 7th meeting on evaluation of pandemic influenza vaccines in clinical trials, World Health Organization, Geneva, 17-18 February 2011. Vaccine 2011; 29 (44): 7579-86
51. Baz M, Luke CJ, Cheng X, et al. H5N1 vaccines in humans. Virus Res 2013; 178 (1): 78-98
52. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014; 209 (12): 1860-9
53. Rudenko L, Naykhin A, Donina S, et al. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccin Immunother 2015
54. Halliley JL, Khurana S, Krammer F, et al. High affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infe Dis 2015. [Epub ahead of print]
55. Novel Swine-Origin Influenza AVIT. Dawood FS, Jain S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360 (25): 2605-15
56. Rudenko L, Van Den Bosch H, Kiseleva I, et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011; 29 (Suppl 1): A40-4
57. Mallory RM, Malkin E, Ambrose CS, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010; 5 (10): e13755
58. Kulkarni PS, Agarkhedkar S, Lalwani S, et al. Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case control study. Hum Vaccin Immunother 2014; 10 (3): 566-71
59. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6 (8): e23085
60. Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog 2014; 10 (1): e1003831
61. Yang H, Chang JC, Guo Z, et al. Structural stability of influenza A(H1N1)pdm09 virus hemagglutinins. J Virol 2014; 88 (9): 4828-38
62. CDC. CDC Statement on LAIV Effectiveness and Vaccination of Children, 2014,www.cdc.gov/flu/news/nasal-spray-effectiveness.htm [Last accessed 14 July 2015]
63. WHO. Meeting on live attenuated influenza vaccines in low and middle income countries. Executive summary. 2015. Available from: www.who.int/influenzavaccinesplan/ExecutiveSummaryLAIVmeetingFINAL.pdf
64. Stittelaar KJ, Veldhuis Kroeze EJ, Rudenko L, et al. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine 2011; 29 (49): 9265-70
65. Ortiz JR, Goswami D, Lewis KD, et al. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. Vaccine 2015; 33 (29): 3415-21
66. Zang Y, Du D, Ge P, et al. Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines. Hum Vaccin Immunother 2014; 10 (12): 3642-8
67. Minor PD, Engelhardt OG, Wood JM, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27 (22): 2907-13
68. Milian E, Kamen AA. Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. Biomed Res Int 2015; 2015: 504831
69. Youil R, Su Q, Toner TJ, et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods 2004; 120 (1): 23-31
70. Ghendon YZ, Markushin SG, Akopova Ii, et al. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 2005; 23 (38): 4678-84
71. Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009; 27 (46): 6460-3
72. George M, Farooq M, Dang T, et al. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 2010; 106 (6): 906-17
73. Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010; 28 (22): 3848-55
74. Ilyushina NA, Ikizler MR, Kawaoka Y, et al. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol 2012; 86 (21): 11725-34
75. Nechaeva EA, Radaeva IF, Senkina TY, et al. The comparative study of influenza vaccine virus strain reproduction as a function of different methods for MDCK cell cultivation. Biotechnol Russia 2011; 3: 38-44
76. Palker T, Kiseleva I, Johnston K, et al. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg-or cell culture-derived reassortants. Virus Res 2004; 105 (2): 183-94
77. Mazurkova NA, Desheva Iu A, Shishkina LN, et al. [Immunogenicity of influenza virus H5N2 vaccine strain samples produced by roller cultivation in media with plant derived components]. Zh Mikrobiol Epidemiol Immunobiol 2011 (3): 48-52
78. Nechaeva EA, Senkina TY, Ryzhikov AB, et al. Development of live cultural pandemic influenza vaccine Vector-Flu. BMC Proceedings 2011; 5 (Suppl 8): P104
79. Heldens J, Hulskotte E, Voeten T, et al. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers. Vaccine 2014; 32 (39): 5118-24
80. Romanova J, Katinger D, Ferko B, et al. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res 2004; 103 (1-2): 187-93
81. Katinger H, Egorov A, Ferko B, et al. Live influenza vaccine and method of manufacture. Live influenza vaccine and method of manufacture. WO024876 A2; 2002
82. Lee KH, Seo SU, Song JM, et al. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine 2006; 24 (11): 1966-74
83. Seo SU, Byun YH, Lee EY, et al. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine 2008; 26 (7): 874-81
84. Jang YH, Lee EY, Byun YH, et al. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains. Vaccine 2014; 32 (5): 535-43
85. Jang YH, Jung EJ, Byun YH, et al. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. Vaccine 2013; 31 (33): 3339-46
86. Jang YH, Byun YH, Lee DH, et al. Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets. Vaccine 2013; 31 (9): 1320-7
87. Tsybalova LM, Gorev NE, Potapchuk MV, et al. [Characterization of cold-adapted influenza strain A/HongKong/1/68/162/35 as a potential donor of attenuation and high reproduction]. Vopr Virusol 2012; 57 (6): 13-17
88. Potapchuk MV, Repko IA, Sergeeva MV, et al. [Characterization of influenza virus reassortants based on new donor strain A/HK/1/68/162/35(H3N2)]. Vopr Virusol 2012; 57 (6): 42-6
89. Finch C, Li W, Perez D. Design of Alternative Live Attenuated Influenza Virus Vaccines. In: Oldstone MBA, Compans RW.,. editors. Influenza Pathogenesis and Control. Volume 2 Springer International Publishing, Switzerland; 2015. p. 205-35
90. Egorov A, Brandt S, Sereinig S, et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998; 72 (8): 6437-41
91. Ferko B, Stasakova J, Romanova J, et al. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol 2004; 78 (23): 13037-45
92. Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 2009; 27 (21): 2851-7
93. Romanova J, Krenn BM, Wolschek M, et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009; 4 (6): e5984
94. Le Bon A, Schiavoni G, Dagostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14 (4): 461-70
95. Steel J, Lowen AC, Pena L, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009; 83 (4): 1742-53
96. Wressnigg N, Shurygina AP, Wolff T, et al. Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. J Gen Virol 2009; 90 (Pt 2): 366-74
97. Wacheck V, Egorov A, Groiss F, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infec Dis 2010; 201 (3): 354-62
98. Morokutti A, Muster T, Ferko B. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. Vaccine 2014; 32 (17): 1897-900
99. FDA. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. [Last accessed 14 July 2014]
100. The European agency for the evaluation of medical products CFPMP. Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/96. Available from: www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2009/09/WC500003945.pdf. [Last accessed 14 July 2014]
101. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70 (4): 767-77
102. Meiklejohn G, Kempe CH, Thalman WG, Lennette EH. Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic. Am J Hyg 1952; 55 (1): 12-21
103. Jang YH, Byun YH, Lee YJ, et al. Cold-adapted pandemic. 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virology 2012; 86 (10): 5953-8
104. Lau YF, Wright AR, Subbarao K. The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection. J Virol 2012; 86 (9): 5089-98
105. Naykhin A, Petukhova G, Chirkova T, et al. Virus-specific CD4+ and CD8+ memory T-cells in young volunteers after immunization with pandemic live attenuated reassortant influenza vaccines A(H5N2) and A(H1N1). Influenza Other Respir Viruses 2011; 5 (Suppl 1): 195-201
106. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011; 10 (8): 1131-41
107. Dolfi DV, Mansfield KD, Kurupati RK, et al. Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013; 8 (10): e77164
108. Zens KD, Farber DL. Memory CD4 T cells in influenza. Curr Top Microbiol Immunol 2015; 386: 399-421
109. Takahashi Y. Memory B cells in systemic and mucosal immune response: implications for successful vaccination. Biosci Biotechnol Biochem 2007; 71 (10): 2358-66
110. Ohmit SE, Petrie JG, Cross RT, et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204 (12): 1879-85
111. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30 (12): 1081-5
112. Meeyai A, Praditsitthikorn N, Kotirum S, et al. Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysis. PLoS Med 2015; 12 (5): e1001829
113. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356 (7): 685-96
114. Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 2013; 31 (37): 3766-71
115. Clinicaltrials.Gov. Study of immune responses in healthy adults receiving live influenza virus vaccines. Available from: https://clinicaltrials.gov/ct2/show/NCT01674205
116. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015; 14 (3): 167-82
117. Lee YT, Kim KH, Ko EJ, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014 2014; 3 (1): 12-28
118. Li J, Arevalo MT, Zeng M. Engineering influenza viral vectors. Bioengineered 2013; 4 (1): 9-14